- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00814710
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age
Primary Vaccination Course in Healthy Children Receiving the Pneumococcal Vaccine GSK 1024850A Co-administered With Tritanrix™-HepB/Hib at 6, 10 and 14 Weeks of Age
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Kolkata, India, 700073
- GSK Investigational Site
-
Ludhiana, India, 141 008
- GSK Investigational Site
-
Pune, India
- GSK Investigational Site
-
Vellore, India, 632004
- GSK Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female subjects between, and including 6-10 weeks of age at the time of the first vaccination.
- Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.
- Written or oral, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward. Where parent(s)/guardian(s) are illiterate, the consent form will be countersigned by a witness.
- Free of any known or suspected health problems (as established by medical history and clinical examination before entering into the study).
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
- A family history of congenital or hereditary immunodeficiency.
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (with the exception of hepatitis B immunoglobulins at birth).
- Previous vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception of hepatitis B vaccination at birth or at least 30 days before the subject's first study visit).
- History of, or intercurrent, diphtheria, tetanus, pertussis, hepatitis B, Streptococcus and Haemophilus influenzae type b disease.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.
- History of any neurological disorders or seizures.
- Major congenital defects or serious chronic illness.
- Acute disease at the time of enrolment.
- Babies for which birth weight is < 2 kilogram.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Synflorix & Tritanrix-HebB/Hib Group
Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
|
Iniezione intramuscolare, 3 dosi
Intramuscular injection, 3 doses
Altri nomi:
|
Comparatore attivo: Hiberix group & Tritanrix-HebB Group
Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
|
Intramuscular injection, 3 doses
Altri nomi:
Intramuscular injection, 3 doses
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes
Lasso di tempo: One month after primary immunization (month 3)
|
Concentrations were expressed as Geometric Mean Concentrations (GMCs) in microgram per milliliter (µg/mL). Pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. |
One month after primary immunization (month 3)
|
Concentration of Antibody Against Protein D (PD)
Lasso di tempo: One month after primary immunization (month 3)
|
Concentrations were expressed as GMCs GSK's 22F-inhibition in enzyme-linked-immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
|
One month after primary immunization (month 3)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Subjects With Opsonophagocytic Activity Against Pneumococcal Serotypes
Lasso di tempo: One month after primary immunization (month 3)
|
Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A. Opsonophagocytic activity was defined as the dilution of serum (opsonic titer) able to sustain 50% killing of live pneumococci under the assay conditions. The cut-off of the assay was an opsonic titer equal to or greater than 8. |
One month after primary immunization (month 3)
|
Number of Subjects With Antibody Concentrations Against Pneumococcal Serotypes Equal to or Above Cut-off Value
Lasso di tempo: One month after primary immunization
|
Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A. The cut-off was defined as 0.20 microgram per milliliter (µg/mL). |
One month after primary immunization
|
Concentrations of Antibodies Against Pneumococcal Cross-reactive Serotypes
Lasso di tempo: One month after primary immunization (month 3)
|
Concentrations were expressed as GMCs in µg/mL.
Pneumococcal cross-reactive serotypes included 6A and 19A.
|
One month after primary immunization (month 3)
|
Number of Subjects Seropositive for Pneumococcal Serotypes
Lasso di tempo: One month after primary immunization (month 3)
|
Vaccine pneumococcal serotypes included 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. Cross-reactive pneumococcal serotypes included 6A and 19A. Seropositivity was defined as a titer equal to or greater than 0.05 µg/mL |
One month after primary immunization (month 3)
|
Number of Subjects Seropositive for Protein D (PD)
Lasso di tempo: One month after primary immunization (month 3)
|
Seropositivity for PD was defined greater than or equal to 100 EL.U/mL.
|
One month after primary immunization (month 3)
|
Concentration of Antibody Against Polyribosyl-ribitol Phosphate (PRP)
Lasso di tempo: One month after primary immunization (month 3)
|
Concentration is expressed as GMC in µg/mL.
|
One month after primary immunization (month 3)
|
Concentration of Antibodies Against Diphteria (Anti-DT) and Tetanus (Anti-TT)
Lasso di tempo: One month after primary immunization (month 3)
|
Concentrations were expressed as GMCs in international units per milliliter (IU/mL).
|
One month after primary immunization (month 3)
|
Concentration of Antibody Against Bordetella Pertussis (B. Pertussis)
Lasso di tempo: One month after primary immunization (month 3)
|
Concentration was expressed as GMC in EL.U/mL.
|
One month after primary immunization (month 3)
|
Concentration of Antibody Against Hepatitis B (Anti-HBs) by Enzyme-Linked ImmunoSorbent Assay (ELISA).
Lasso di tempo: One month after primary immunization (month 3)
|
Concentration was expressed as GMC in milli international units per milliliter (mIU/mL).
As a decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL), the table shows results following partial or complete retesting/reanalysis.
|
One month after primary immunization (month 3)
|
Number of Subjects Seropostive for B. Pertussis
Lasso di tempo: One month after primary immunization (month 3)
|
Seropositivity was defined as and antibody concentration equal to or greater than 15 EL.U/mL.
|
One month after primary immunization (month 3)
|
Number of Seroprotected Subjects (Anti-DT, Anti-TT, Anti-PRP, Anti-HBs)
Lasso di tempo: One month after primary immunization (month 3)
|
Seroprotection was defined as: Anti-DT antibody concentration equal to or greater than 0.1 IU/mL. Anti-TT antibody concentration equal to or greater than 0.1 IU/mL. Anti-PRP antibody concentration equal to or greater than 0.15 µg/mL Anti-HBs antibody concentration greater than or equal to 10 mIU/mL. |
One month after primary immunization (month 3)
|
Number of Seroprotected Subjects (Anti-PRP Above the Cut-off of 1.0 µg/mL)
Lasso di tempo: One month after primary immunization (month 3)
|
Anti-PRP antibody concentration equal to or greater than 1.0 µg/mL.
|
One month after primary immunization (month 3)
|
Number of Subjects With Solicited Local and General Symptoms
Lasso di tempo: Within 4 days (day 0-3) after vaccination
|
Solicited local symptoms included pain, redness and swelling.
Solicited general symptoms included drowsiness, fever (equal to or above 38 degrees Celsius and above 39 degrees Celsius), irritability and loss of appetite.
|
Within 4 days (day 0-3) after vaccination
|
Number of Subjects With Unsolicited Adverse Events (AEs)
Lasso di tempo: Within 31 days (day 0-30) after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms |
Within 31 days (day 0-30) after vaccination
|
Number of Subjects With Serious Adverse Events (SAEs)
Lasso di tempo: Following first vaccination (Month 0) throughout the entire study period (month 3)
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
Following first vaccination (Month 0) throughout the entire study period (month 3)
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Lalwani S, Chatterjee S, Chhatwal J, Simon A, Ravula S, Francois N, Mehta S, Strezova A, Borys D. Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India. Clin Vaccine Immunol. 2014 Sep;21(9):1292-300. doi: 10.1128/CVI.00068-14. Epub 2014 Jul 9.
- Lalwani S, Chatterjee S, Chhatwal J, Verghese VP, Mehta S, Shafi F, Borys D, Moreira M, Schuerman L. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study. Hum Vaccin Immunother. 2012 May;8(5):612-22. doi: 10.4161/hv.19287. Epub 2012 May 1.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Infezioni
- Infezioni delle vie respiratorie
- Malattie delle vie respiratorie
- Polmonite
- Malattie polmonari
- Infezioni batteriche
- Infezioni batteriche e micosi
- Infezioni batteriche Gram-positive
- Polmonite, batterica
- Infezioni pneumococciche
- Polmonite, pneumococco
- Infezioni streptococciche
- Effetti fisiologici delle droghe
- Fattori immunologici
- Vaccino coniugato pneumococcico eptavalente
Altri numeri di identificazione dello studio
- 111188
- 2011-004644-22 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Dati/documenti di studio
-
Protocollo di studio
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Set di dati del singolo partecipante
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di segnalazione del caso annotato
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Rapporto di studio clinico
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Modulo di consenso informato
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Specifica del set di dati
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
-
Piano di analisi statistica
Identificatore informazioni: 111188Commenti informativi: For additional information about this study please refer to the GSK Clinical Study Register
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Streptococco polmonare
-
Universidad de la SabanaReclutamentoPolmonite acquisita in comunità | Infezione da streptococco polmonare | Polmonite da Streptococcus Pneumoniae | Streptococcus Pneumoniae Infezione InvasivaColombia
-
King Abdulaziz UniversityCompletatoConta di carie dentale e Streptococcus MutansArabia Saudita
-
Olga TyuminaClinics of the Federal State Budgetary Educational Institution SSMU; Samara Regional...SconosciutoCOVID-19 | Covid19 | PNEUMONIA DA SARS-CoV-2Federazione Russa
-
State-Financed Health Facility "Samara Regional...Clinics of the Federal State Budgetary Educational Institution SSMU; Samara Regional...CompletatoCOVID-19 | Covid19 | PNEUMONIA DA SARS-CoV-2Federazione Russa
-
Walvax Biotechnology Co., Ltd.CompletatoMalattie causate da sierotipi di Streptococcus Pneumoniae
-
University of MilanSconosciutoStreptococcus Pneumoniae Carrello nasofaringeoItalia
-
Arto PalmuGlaxoSmithKlineCompletatoTrasporto nasofaringeo di Streptococcus PneumoniaeFinlandia
-
GlaxoSmithKlineRitiratoImmunizzazione contro Streptococcus Pneumoniae
-
University of OxfordPfizerSconosciutoPolmonite streptococcica | Infezione da streptococco polmonare | Streptococcus pneumoniae, malattia invasivaRegno Unito
-
VA Office of Research and DevelopmentMichael E. DeBakey VA Medical CenterCompletatoPolmonite | Infezioni pneumococciche | Infezioni, Streptococcus PneumoniaeStati Uniti